Abstract
Optimization of antiischemic therapy is necessary in many patients with stable forms of coronary heart disease after or during revascularization. From the standpoint of current guidelines, the addition of second-line drugs, in particular ranolazine, to beta-blockers and/or calcium antagonists is considered during anginal attacks due to incomplete revascularization, to prevent myocardial damage during percutaneous coronary interventions, and in cases when revascularization is not possible. The results of many clinical studies have proven the antiischemic effect and safety of ranolazine after coronary artery stenting. Potential advantages of ranolazine compared with other second-line antianginal drugs are the absence of significant changes in hemodynamic parameters, good tolerability and proven antiarrhythmic effects. Key words: chronic ischemic heart disease, percutaneous coronary intervention, ranolazine.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
